Search research articles
Contact Us
Filters
Showing results (181-190 of 267) with videos related to
Page
of 27
Sort By:
The Lancet Regional Health. Europe
|
April 18, 2025
Correction to "Impact of vaccination with third generation modified vaccinia Ankara and sexual behaviour on mpox incidence in men who have sex with men: analysis among participants of the ANRS-174 DOXYVAC trial" [The Lancet Regional Health-Europe 45, October 2024, 101020]
Jade Ghosn, Lambert Assoumou, Moussa Ouattara, et al.
Antimicrobial Agents and Chemotherapy
|
May 20, 2009
Protease inhibitor resistance analysis in the MONARK trial comparing first-line lopinavir-ritonavir monotherapy to lopinavir-ritonavir plus zidovudine and lamivudine triple therapy
Constance Delaugerre, Philippe Flandre, Marie Laure Chaix, et al.
The Journal of Antimicrobial Chemotherapy
|
October 7, 2022
Impact on renal function of daily and on-demand HIV pre-exposure prophylaxis in the ANRS-PREVENIR study
Geoffroy Liegeon, Lambert Assoumou, Jade Ghosn, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
April 2, 2026
Acute Hepatitis B among PWH Switched to Long-Acting Cabotegravir/Rilpivirine: The Context Matters
Rémi Rouget, Nadia Valin, Antoine Bachelard, et al.
Journal of the International AIDS Society
|
June 12, 2021
No need for secondary Pneumocystis jirovecii pneumonia prophylaxis in adult people living with HIV from Europe on ART with suppressed viraemia and a CD4 cell count greater than 100 cells/µL
Andrew Atkinson, Jose M Miro, Amanda Mocroft, et al.
The Journal of Antimicrobial Chemotherapy
|
November 4, 2025
Switching from etravirine to doravirine in virologically suppressed people with HIV: results from the French multicentre SWEED observational study
Romain Palich, Jade Ghosn, Karine Lacombe, et al.
Antimicrobial Agents and Chemotherapy
|
February 6, 2008
Antiretroviral therapy with a twice-daily regimen containing 400 milligrams of indinavir and 100 milligrams of ritonavir in human immunodeficiency virus type 1-infected women during pregnancy
Jade Ghosn, Ines De Montgolfier, Chantal Cornélie, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
July 22, 2010
Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL?
, Amanda Mocroft, Peter Reiss, et al.
Antimicrobial Agents and Chemotherapy
|
July 15, 2020
Effect of Pregnancy on Unbound Raltegravir Concentrations in the ANRS 160 RalFe Trial
Yi Zheng, Déborah Hirt, Sandrine Delmas, et al.
AIDS (London, England)
|
October 17, 2018
Viral rebound in semen after antiretroviral treatment interruption in an HIV therapeutic vaccine double-blind trial
Romain Palich, Jade Ghosn, Antoine Chaillon, et al.
Page
of 27
Search research articles
Search
Showing results (181-190 of 267) with videos related to
Sort By:
Page
of 27
The Lancet Regional Health. Europe
|
April 18, 2025
Correction to "Impact of vaccination with third generation modified vaccinia Ankara and sexual behaviour on mpox incidence in men who have sex with men: analysis among participants of the ANRS-174 DOXYVAC trial" [The Lancet Regional Health-Europe 45, October 2024, 101020]
Jade Ghosn, Lambert Assoumou, Moussa Ouattara, et al.
Antimicrobial Agents and Chemotherapy
|
May 20, 2009
Protease inhibitor resistance analysis in the MONARK trial comparing first-line lopinavir-ritonavir monotherapy to lopinavir-ritonavir plus zidovudine and lamivudine triple therapy
Constance Delaugerre, Philippe Flandre, Marie Laure Chaix, et al.
The Journal of Antimicrobial Chemotherapy
|
October 7, 2022
Impact on renal function of daily and on-demand HIV pre-exposure prophylaxis in the ANRS-PREVENIR study
Geoffroy Liegeon, Lambert Assoumou, Jade Ghosn, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
April 2, 2026
Acute Hepatitis B among PWH Switched to Long-Acting Cabotegravir/Rilpivirine: The Context Matters
Rémi Rouget, Nadia Valin, Antoine Bachelard, et al.
Journal of the International AIDS Society
|
June 12, 2021
No need for secondary Pneumocystis jirovecii pneumonia prophylaxis in adult people living with HIV from Europe on ART with suppressed viraemia and a CD4 cell count greater than 100 cells/µL
Andrew Atkinson, Jose M Miro, Amanda Mocroft, et al.
The Journal of Antimicrobial Chemotherapy
|
November 4, 2025
Switching from etravirine to doravirine in virologically suppressed people with HIV: results from the French multicentre SWEED observational study
Romain Palich, Jade Ghosn, Karine Lacombe, et al.
Antimicrobial Agents and Chemotherapy
|
February 6, 2008
Antiretroviral therapy with a twice-daily regimen containing 400 milligrams of indinavir and 100 milligrams of ritonavir in human immunodeficiency virus type 1-infected women during pregnancy
Jade Ghosn, Ines De Montgolfier, Chantal Cornélie, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
July 22, 2010
Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL?
, Amanda Mocroft, Peter Reiss, et al.
Antimicrobial Agents and Chemotherapy
|
July 15, 2020
Effect of Pregnancy on Unbound Raltegravir Concentrations in the ANRS 160 RalFe Trial
Yi Zheng, Déborah Hirt, Sandrine Delmas, et al.
AIDS (London, England)
|
October 17, 2018
Viral rebound in semen after antiretroviral treatment interruption in an HIV therapeutic vaccine double-blind trial
Romain Palich, Jade Ghosn, Antoine Chaillon, et al.
Page
of 27